Invitae Hereditary Prostate Cancer Panel
Use
The Invitae Hereditary Prostate Cancer Panel analyzes genes associated with adult-onset predisposition to prostate cancer. This panel aids in the identification of genetic heterogeneity that complicates phenotype-based selection of a definitive cause. Testing helps confirm clinical diagnoses, predict disease prognosis and progression, aid in early detection, and inform family planning or genetic counseling. Enrollment in clinical trials may also be facilitated. The test is for heritable germline mutations and is not suitable for detecting somatic mutations in tumor tissue.
Special Instructions
The panel permits customization by removing specific genes. It is performed in a CAP-accredited and CLIA-certified lab using NGS technology. Contact client services for questions. Validity and limitations will be detailed in the report.
Limitations
The test achieves >99% analytical sensitivity and specificity for certain variants, but structural rearrangements or variants in complex sequences may not be detected. Rarely, inaccuracies may occur with samples from blood transfusion or those with hematolymphoid neoplasm. Promoter, non-coding exons, and other regions beyond designated target regions are generally not covered unless specified.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)